[EQUITIES] ‘Samsung BioLogics to soar on novel biosimilars’ – The Investor

The Investor

[EQUITIES] ‘Samsung BioLogics to soar on novel biosimilars’
The Investor
[THE INVESTOR] Samsung BioLogics continues to win contract manufacturing orders, and when the third factory begins to fully operate in 2019 its revenue will hike, said Yuanta Securities on Aug. 31, suggesting a “buy” recommendation and 360,000 won …

Leave a Reply

Your email address will not be published. Required fields are marked *

*

3 × three =